在心力衰竭中治疗缺铁的治疗方法
Aamir Shamsi1, Antonio Cannata1,2, Susan Piper1
1Department of Cardiology, King's College Hospital London, Denmark Hill, Brixton, London, SE5 9RS, UK.
Current cardiology reports
|June 17, 2023
概括
缺铁 (ID) 在心力衰竭 (HF) 中很常见,并且与更糟糕的结果有关. 在HF患者治疗ID可以改善生活质量,无论贫血状况如何.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 血液学 血液学 血液学
背景情况:
- 心力衰竭 (HF) 经常与缺铁 (ID) 一起存在,这是一种由铁含量不足定义的疾病.
- ID被认为是HF的显著并发症,即使没有贫血.
- ID与HF患者的发病率和死亡率增加有关.
研究的目的:
- 审查当前关于测量和治疗高频ID的证据.
- 为了覆盖心力衰竭与减少喷射分数 (HFrEF) 和心力衰竭与保存喷射分数 (HFpEF) 的ID.
- 为了确定在各种HF病因的ID管理的知识差距.
主要方法:
- 对当代证据的文献评论.
- 对专注于ID测量和治疗策略的研究进行分析.
- 对不同HF亚型和原因的数据进行检查.
主要成果:
- 铁缺乏症在HF患者中很普遍.
- 纠正ID可以提高HF患者的功能状态,运动耐受性和生活质量.
- 无论是否存在贫血,都会观察到ID校正的好处.
结论:
- 缺铁是心力衰竭中可改变的并发症.
- 识别和治疗ID为HF管理提供了治疗潜力.
- 照顾HF患者的临床医生应该了解ID治疗的理由和方法.
相关概念视频
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure VII: Nursing Interventions
118
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
118
Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641


